From: Proteomic analysis of sputum reveals novel biomarkers for various presentations of asthma
 | Healthy controls | Patients with asthma | P Controls vs. Patients | P CA vs. CVA vs. CVTA | |||
---|---|---|---|---|---|---|---|
Total | CA | CVA | CTVA | ||||
No. of patients | 30 | 87 | 30 | 27 | 30 | Â | Â |
Age, years | 44.0 ± 12.8 | 42.1 ± 13.8 | 41.4 ± 13.6 | 45.0 ± 13.2 | 40.1 ± 14.4 | 0.501 | 0.399 |
Male sex, no. (%) | 15 (50) | 42 (48) | 14 (47) | 10 (37) | 18 (60) | 0.871 | 0.218 |
Smoking status | |||||||
 Smokers, no. (%) | 9 (30) | 13 (17) | 3 (10) | 4 (15) | 6 (20) | 0.069 | 0.554 |
 Pack/years | 33.1 ± 42.0 | 20.5 ± 18.9 | 21.6 ± 25.0 | 22.5 ± 20.6 | 21.5 ± 17.4 | 0.322 | 0.997 |
History of atopy, no. (%) | 6 (20) | 30 (34) | 13 (43) | 10 (37) | 7 (23) | 0.138 | 0.250 |
BMI, kg/m2 | 24.3 ± 3.7 | 23.2 ± 2.8 | 23.6 ± 2.4 | 23.7 ± 2.8 | 22.5 ± 3.1 | 0.085 | 0.187 |
Serum IgE, IU/mL | 1.5 ± 0.6 | 1.9 ± 0.7 | 1.9 ± 0.8 | 1.8 ± 0.8 | 2.0 ± 0.6 | 0.014 | 0.668 |
FEV1, %Predicted | 99.1 ± 13.5 | 85.9 ± 16.1 | 80.7 ± 14.6 | 90.5 ± 17.6 | 87.1 ± 15.0 | <0.001 | 0.062 |
FEV1/FVC ratio, % | 80.6 ± 16.1 | 75.0 ± 11.5 | 74.1 ± 8.0 | 80.0 ± 8.2 | 71.5 ± 15.3 | 0.044 | 0.017 |
Blood eosinophils, % | 2.0 ± 0.9 | 3.8 ± 6.0 | 5.6 ± 4.3 | 4.6 ± 9.5 | 2.5 ± 1.9 | 0.485 | 0.307 |
Sputum eosinophils, % | 0.4 ± 0.8 | 1.9 ± 2.2 | 1.5 ± 1.3 | 2.1 ± 1.5 | 2.3 ± 3.2 | <0.001 | 0.417 |
FeNO, ppb | 16.1 ± 10.6 | 27.3 ± 27.6 | 34.3 ± 33.1 | 23.6 ± 24.5 | 23.4 ± 23.3 | 0.002 | 0.229 |
Anxiety and depression | |||||||
 SAS score | 31.8 ± 7.2 | 42.1 ± 10.8 | 42.0 ± 10.8 | 43.3 ± 9.8 | 41.2 ± 11.9 | <0.001 | 0.763 |
 SDS score | 34.0 ± 11.4 | 43.8 ± 11.0 | 44.9 ± 11.3 | 44.9 ± 8.7 | 41.6 ± 12.4 | <0.001 | 0.416 |